CoChat

The DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index.

Oral route lipopolysaccharide as a potential dementia preventive agent inducing neuroprotective microglia

Open access
Mizobuchi, Haruka · 2023 · Frontiers in Immunology

Abstract

In today’s aging society, dementia is an urgent problem to be solved because no treatment or preventive methods have been established. This review focuses on oral administration of lipopolysaccharide (LPS), an outer membrane component of Gram-negative bacteria, as a novel preventive drug for dementia. LPS is also called endotoxin and is well known to induce inflammation when administered systemically. On the other hand, although we humans routinely ingest LPS derived from symbiotic bacteria of edible plants, the effect of oral administration of LPS has hardly been studied. Recently, oral administration of LPS was reported to prevent dementia by inducing neuroprotective microglia. Furthermore, it has been suggested that colony stimulating factor 1 (CSF1) is involved in the dementia prevention mechanism by oral administration of LPS. Thus, in this review, we summarized the previous studies of oral administration of LPS and discussed the predicted dementia prevention mechanism. In addition, we showed the potential of oral LPS administration as a preventive drug for dementia by highlighting research gaps and future issues for clinical application development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1110583

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Hypothetical mechanism of induction of neuroprotective microglia by OAL. OAL promotes m-CSF1 expression on peripheral leukocytes. In the physiological state, peripheral leukocytes communicate with healthy CNS cells in the choroid plexus for homeostasis maintenance. In pathological conditions, the microglial CSF1R activation by m-CSF1 on peripheral leukocytes induces transformation to neuroprotective microglia, which contributes to the prevention of dementia. OAL, oral administration of LPS; m-CSF1, membranous colony stimulating factor 1; CNS, central nervous system; CSF1R, CSF1 receptor.
Figure 1 Hypothetical mechanism of induction of neuroprotective microglia by OAL. OAL promotes m-CSF1 expression on peripheral leukocytes. In the physiological state, peripheral leukocytes communicate with healthy CNS cells in the choroid plexus for homeostasis maintenance. In pathological conditions, the microglial CSF1R activation by m-CSF1 on peripheral leukocytes induces transformation to neuroprotective microglia, which contributes to the prevention of dementia. OAL, oral administration of LPS; m-CSF1, membranous colony stimulating factor 1; CNS, central nervous system; CSF1R, CSF1 receptor.CC BY · PubMed Central
Figure 2 Issues to be solved for clinical application of OAL. Issues to be resolved in the future for clinical application of OAL can be broadly divided into basic research, non-clinical studies, and clinical studies. First, in basic research, the OAL mechanism involving CSF1R signaling must be elucidated. It will also be important to extract LPS with high efficacy through LPS screening. Next, in non-clinical studies, it is necessary to improve the safety and efficacy of OAL through pharmacological, pharmacokinetic, and toxicity studies. Safety in patients with specific and noteworthy medical histories such as mucositis must also be verified there. Based on the above studies, in the final clinical trial, it is necessary to confirm the safety and efficacy in humans and determine the optimal dosage. OAL, oral administration of LPS; m-CSF1, membranous colony stimulating factor 1; CSF1R, CSF1 receptor; TLR4, toll-like receptor 4.
Figure 2 Issues to be solved for clinical application of OAL. Issues to be resolved in the future for clinical application of OAL can be broadly divided into basic research, non-clinical studies, and clinical studies. First, in basic research, the OAL mechanism involving CSF1R signaling must be elucidated. It will also be important to extract LPS with high efficacy through LPS screening. Next, in non-clinical studies, it is necessary to improve the safety and efficacy of OAL through pharmacological, pharmacokinetic, and toxicity studies. Safety in patients with specific and noteworthy medical histories such as mucositis must also be verified there. Based on the above studies, in the final clinical trial, it is necessary to confirm the safety and efficacy in humans and determine the optimal dosage. OAL, oral administration of LPS; m-CSF1, membranous colony stimulating factor 1; CSF1R, CSF1 receptor; TLR4, toll-like receptor 4.CC BY · PubMed Central
Figure 3 The importance of healthy mucosa for disease-preventing effect of OAL. In healthy mucosa, LPS taken by the oral route does not enter the blood, but acts on the immune system in the oral or upper gastrointestinal mucosa and induces the expression of m-CSF1 in peripheral leukocytes. The leukocytes that highly express m-CSF1 (m-CSF1high leukocytes) patrol the choroid plexus and maintain brain homeostasis. Upon sensing pathological conditions, m-CSF1high leukocytes activate microglial CSF1R signaling in the choroid plexus, inducing transformation to neuroprotective microglia to prevent neuropathy. On the other hand, when the mucosal barrier is disrupted due to mucositis, LPS may be absorbed into the blood and induce inflammation and shock when it circulates systemically. m-CSF1, membranous colony stimulating factor 1; CSF1R, CSF1 receptor.
Figure 3 The importance of healthy mucosa for disease-preventing effect of OAL. In healthy mucosa, LPS taken by the oral route does not enter the blood, but acts on the immune system in the oral or upper gastrointestinal mucosa and induces the expression of m-CSF1 in peripheral leukocytes. The leukocytes that highly express m-CSF1 (m-CSF1high leukocytes) patrol the choroid plexus and maintain brain homeostasis. Upon sensing pathological conditions, m-CSF1high leukocytes activate microglial CSF1R signaling in the choroid plexus, inducing transformation to neuroprotective microglia to prevent neuropathy. On the other hand, when the mucosal barrier is disrupted due to mucositis, LPS may be absorbed into the blood and induce inflammation and shock when it circulates systemically. m-CSF1, membranous colony stimulating factor 1; CSF1R, CSF1 receptor.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 85 references

Research works printed but not linked: 1

  1. 2017, Global action plan on the public health response to dementia 2017 - 2025

Cited by

See all 11

Metadata

Authors
Mizobuchi, H.
Affiliations
The University of Tokyo (JP)
Corresponding author
Mizobuchi, Haruka
Venue
Frontiers in Immunology
Published
2023-03-09
Volume
14
Pages
1110583-1110583
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4323666621
Cited by
11
References
87
Citations by year
2026: 3 · 2025: 4 · 2024: 3 · 2023: 1
FWCI
0.29
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Agriculture and Food Research Organization
  • Council for Science, Technology and Innovation
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
lipopolysaccharide, dementia prevention, oral administration, microglia, neuroprotection, colony-stimulating factor 1, endotoxin, gut microbiota, neuroinflammation, Gram-negative bacteria
MeSH terms
Administration, Oral, Dementia, Endotoxins, Humans, Lipopolysaccharides, Microglia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral route lipopolysaccharide as a potential dementia preventive agent inducing neuroprotective microglia. https://app.cochat.ai/papers/10.3389/fimmu.2023.1110583
The paper
Mizobuchi, H. (2023). Oral route lipopolysaccharide as a potential dementia preventive agent inducing neuroprotective microglia. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1110583

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.